About half of trial participants developed antibodies to tesamorelin, and what that did and did not do

Published 26 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
The label reports that about half of participants treated with tesamorelin for 26 weeks developed anti-tesamorelin IgG antibodies, and that most of these also bound endogenous growth hormone-releasing hormone. Antibody-positive participants showed a similar reduction in visceral fat to antibody-negative ones, and IGF-1 responses were comparable, so the antibodies were not neutralising to a degree that mattered in the trials. They were associated with a somewhat higher rate of injection-site reactions. Antibody titres declined after discontinuation. Whether long-term antibodies to the native hormone matter is unknown and is stated as such on the label.

Why a modified peptide is immunogenic

A 44-residue peptide is large enough to be seen by the immune system, and the hexenoyl group creates an epitope the body has not encountered. Aggregates in the formulation and repeated administration at one site both raise the chance of a response. The cross-reactivity with native hormone follows from the two sharing 44 residues; the antibodies recognise the shared sequence, not only the modification.

Immunogenicity of this order is common for peptide and protein drugs and is routinely characterised in development.

What the trials found

Efficacy was maintained in antibody-positive participants, and no hypersensitivity pattern tied to antibody status emerged. The theoretical concern — antibodies that neutralise the native releasing hormone and suppress endogenous growth hormone secretion after the drug is stopped — was not observed within the trial follow-up, and the label notes the limits of that follow-up.

The finding is characteristic of non-neutralising binding antibodies.

Why it is here

Because immunogenicity is part of the established pharmacology and a frequent question about any modified peptide. It describes trial findings and no use of the pack.

Tesamorelin is supplied by REVIVE LAB UAE for laboratory research use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not for human or veterinary use, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Tesamorelin Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

Why a modified peptide is immunogenic?

A 44-residue peptide is large enough to be seen by the immune system, and the hexenoyl group creates an epitope the body has not encountered. Aggregates in the formulation and repeated administration at one site both raise the chance of a response. The cross-reactivity with native hormone follows from the two sharing 44 residues; the antibodies recognise the shared sequence, not only the modification.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Tesamorelin Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.